Nick Devoogdt

10.5k total citations · 2 hit papers
155 papers, 8.2k citations indexed

About

Nick Devoogdt is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Nick Devoogdt has authored 155 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Radiology, Nuclear Medicine and Imaging, 74 papers in Oncology and 48 papers in Molecular Biology. Recurrent topics in Nick Devoogdt's work include Monoclonal and Polyclonal Antibodies Research (99 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and HER2/EGFR in Cancer Research (24 papers). Nick Devoogdt is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (99 papers), Radiopharmaceutical Chemistry and Applications (52 papers) and HER2/EGFR in Cancer Research (24 papers). Nick Devoogdt collaborates with scholars based in Belgium, France and United States. Nick Devoogdt's co-authors include Tony Lahoutte, Serge Muyldermans, Vicky Caveliers, Catarina Xavier, Geert Raes, Matthias D’Huyvetter, Marleen Keyaerts, Cécile Vincke, Patrick De Baetselier and Karine Breckpot and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Nick Devoogdt

151 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells

2016 605 citations Fang Zheng, Patrick De Baetselier et al. profile →
Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

2015 341 citations Marleen Keyaerts, Catarina Xavier et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nick Devoogdt Belgium	51	5.1k	3.3k	2.7k	2.1k	961	155	8.2k
Tony Lahoutte Belgium	50	4.5k 0.9×	3.1k 0.9×	2.1k 0.8×	1.3k 0.6×	796 0.8×	163	7.3k
Roland E. Kontermann Germany	47	4.5k 0.9×	5.1k 1.5×	2.6k 0.9×	2.5k 1.2×	604 0.6×	183	8.9k
Andrew Raubitschek United States	53	4.3k 0.8×	2.7k 0.8×	4.3k 1.6×	2.2k 1.0×	1.0k 1.1×	157	9.1k
Guus A.M.S. van Dongen Netherlands	53	5.0k 1.0×	2.4k 0.7×	2.9k 1.1×	912 0.4×	947 1.0×	184	8.6k
David Colcher United States	55	6.7k 1.3×	3.9k 1.2×	3.2k 1.2×	1.9k 0.9×	563 0.6×	208	9.9k
Christoph Rader United States	52	2.4k 0.5×	4.1k 1.2×	3.1k 1.1×	1.7k 0.8×	1.1k 1.1×	180	8.6k
Caius G. Radu United States	44	1.8k 0.3×	3.0k 0.9×	1.5k 0.5×	2.0k 0.9×	685 0.7×	127	6.4k
Vicky Caveliers Belgium	40	3.4k 0.7×	2.1k 0.6×	1.5k 0.6×	829 0.4×	569 0.6×	108	5.1k
Nicole Beauchemin Canada	42	1.8k 0.3×	2.9k 0.9×	1.7k 0.6×	1.5k 0.7×	806 0.8×	114	6.6k
Silvana Canevari Italy	49	1.9k 0.4×	4.4k 1.3×	3.2k 1.2×	2.2k 1.0×	651 0.7×	227	8.7k

Countries citing papers authored by Nick Devoogdt

Since Specialization

Citations

This map shows the geographic impact of Nick Devoogdt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Devoogdt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Devoogdt more than expected).

Fields of papers citing papers by Nick Devoogdt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Devoogdt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Devoogdt. The network helps show where Nick Devoogdt may publish in the future.

Co-authorship network of co-authors of Nick Devoogdt

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Devoogdt. A scholar is included among the top collaborators of Nick Devoogdt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Devoogdt. Nick Devoogdt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ridder, Kirsten De, Wout de Mey, Ana Rita Pombo Antunes, et al.. (2025). Immune modulation following α and β ⁻ radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model. OncoImmunology. 14(1). 2540054–2540054. 1 indexed citations

Cong, Ying, Nick Devoogdt, Philippe Lambin, Ludwig J. Dubois, & Ala Yaromina. (2024). Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management. Cancers. 16(2). 371–371. 9 indexed citations

Fan, Rong, Yanmeng Wang, Timo W.M. De Groof, et al.. (2024). AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia. Theranostics. 14(7). 2656–2674. 6 indexed citations

Antunes, Ana Rita Pombo, Kirsten De Ridder, Tony Lahoutte, et al.. (2024). Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model. European Journal of Nuclear Medicine and Molecular Imaging. 52(2). 444–457. 6 indexed citations

Beule, Nathan De, Ann De Becker, Elke De Bruyne, et al.. (2024). AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies. Experimental Hematology and Oncology. 13(1). 99–99. 4 indexed citations

Xavier, Catarina, Johannes Heemskerk, Nick Devoogdt, et al.. (2023). Phase I Study of [⁶⁸Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I). Journal of Nuclear Medicine. 64(9). 1378–1384. 26 indexed citations

Raes, Geert, Timo W.M. De Groof, Nick Devoogdt, et al.. (2023). A few good reasons to use nanobodies for cancer treatment. European Journal of Immunology. 53(9). e2250024–e2250024. 14 indexed citations

Bridoux, Jessica, Katrijn Broos, Quentin Lecocq, et al.. (2020). Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules. 10(10). 1388–1388. 54 indexed citations

Zhou, Zhengyuan, Nick Devoogdt, Michael R. Zalutsky, & Ganesan Vaidyanathan. (2018). An Efficient Method for Labeling Single Domain Antibody Fragments with ¹⁸F Using Tetrazine-Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. Bioconjugate Chemistry. 29(12). 4090–4103. 40 indexed citations

10.

Broos, Katrijn, Quentin Lecocq, Geert Raes, et al.. (2018). Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics. 8(13). 3559–3570. 89 indexed citations

11.

Debie, Pieterjan, Gezim Bala, Sam Massa, et al.. (2017). Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery. Molecular Pharmaceutics. 14(4). 1145–1153. 87 indexed citations

12.

Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, et al.. (2017). Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics. 16(12). 2828–2839. 55 indexed citations

13.

D’Huyvetter, Matthias, Jens De Vos, Catarina Xavier, et al.. (2017). 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. Clinical Cancer Research. 23(21). 6616–6628. 141 indexed citations

14.

D’Huyvetter, Matthias, Cécile Vincke, Catarina Xavier, et al.. (2014). Targeted Radionuclide Therapy with A ¹⁷⁷Lu-labeled Anti-HER2 Nanobody. Theranostics. 4(7). 708–720. 181 indexed citations

15.

Massa, Sam, Catarina Xavier, Jens De Vos, et al.. (2014). Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging. Bioconjugate Chemistry. 25(5). 979–988. 149 indexed citations

16.

Zheng, Fang, Nick Devoogdt, Yannick Morias, et al.. (2014). Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology. 220(2). 200–209. 27 indexed citations

17.

Xavier, Catarina, Ilse Vaneycken, Matthias D’Huyvetter, et al.. (2013). Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. Journal of Nuclear Medicine. 54(5). 776–784. 190 indexed citations

18.

Movahedi, Kiavash, Steve Schoonooghe, Damya Laoui, et al.. (2012). Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective In Vivo Imaging of Tumor-Associated Macrophages. Cancer Research. 72(16). 4165–4177. 244 indexed citations

19.

Broek, Bieke Van de, Nick Devoogdt, Antoine D’Hollander, et al.. (2011). Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy. ACS Nano. 5(6). 4319–4328. 317 indexed citations

20.

Vaneycken, Ilse, Nick Devoogdt, Naomi Van Gassen, et al.. (2011). Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer. The FASEB Journal. 25(7). 2433–2446. 265 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact